Volunteer established PI education groups 33 years ago
May 08, 2024
Read article
Ask the expert: PI and travel
May 07, 2024
Watch video
Mavorixafor approved for treating WHIM syndrome
May 02, 2024
Read article
Insurers block immunoglobulin access using multiple tactics
May 01, 2024
Read article
Xolremdi
Mavorixafor.
Approved to treat: Warts, hypogammaglobulinemia, immunodeficiency, myelokathexis (WHIM) syndrome.
Ages: 12+
Report side effects/adverse events at 1-866-MED-X4MI (1-866-633-9464).
Twitch streamers CDawg and Ironmouse inspire new plasma donor
April 26, 2024
Read article
Family advocates for son with NEMO
April 25, 2024
Read article
Autoimmune diagnoses may obscure primary immunodeficiency
April 24, 2024
Read article
2023 National Patient Survey report
April 24, 2024
View PDF
¡Estoy inmunodeprimido! tarjeta de emergencia
April 18, 2024
Ver formato de documento portátil
